Docetaxel Injection
Product Images NDC 25021-254

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 25021-254). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Doc0b 0000 01)

Chemical structure of docetaxel anhydrous showing its molecular framework including rings, hydroxyl groups, and ester linkages as depicted in the diagram.*

FDA Label Image

Figure 1 (Doc0b 0000 02)

A line graph comparing Disease-Free Survival (DFS) probability over 72 months for two treatment groups labeled TAC and FAC. The Y-axis shows DFS probability percentage from 0% to 100%, and the X-axis represents time in months from 0 to 72. The TAC group shows consistently higher DFS probability than the FAC group throughout the period.*

FDA Label Image

Figure 2 (Doc0b 0000 03)

A line graph depicting survival probability over time in months, comparing two groups labeled TAC and FAC. The y-axis shows survival probability percentage, and the x-axis shows survival time in months from 0 to 72. Both lines show a gradual decline in survival probability over time.*

FDA Label Image

Figure 3 (Doc0b 0000 04)

A survival curve chart comparing cumulative survival probability over time in months between two groups, T75 and BSC. The graph includes a log-rank p-value of 0.010 indicating statistical significance in overall survival difference between the groups.*

FDA Label Image

Figure 4 (Doc0b 0000 05)

A survival curve graph comparing overall survival probabilities over time (months) between two treatment groups labeled T75 and V/I. The y-axis represents cumulative survival probability, and the x-axis represents survival time in months, with a log-rank p-value of 0.13 indicating no statistically significant difference.*

FDA Label Image

Figure 5 (Doc0b 0000 06)

A survival probability curve chart comparing two treatment regimens over a 30-month period. The x-axis represents survival time in months, and the y-axis represents survival probability. Two curves depict survival outcomes for T75 q3w and M q3w dosing schedules, showing changes in survival probability over time.*

FDA Label Image

Figure 6 (Doc0b 0000 07)

A survival probability curve depicting two treatment groups labeled TCF and CF over 24 months. The y-axis shows probability (%) from 0 to 100, and the x-axis represents time in months from 0 to 24. The curves decline over time with TCF maintaining higher survival probability than CF throughout the period.*

FDA Label Image

Figure 7 (Doc0b 0000 08)

A Kaplan-Meier survival curve chart showing survival probability percentage on the vertical axis and survival time in months on the horizontal axis. Two groups are represented: TCF and CF, with distinct survival probability trajectories over 36 months.*

FDA Label Image

Figure 8 (Doc0b 0000 09)

A Kaplan-Meier survival curve chart comparing progression-free survival (PFS) probabilities over time in months for two groups labeled TPF and PF. The vertical axis represents PFS probability percentage, and the horizontal axis shows progression-free survival time in months up to 42 months.*

FDA Label Image

Figure 9 (Doc0b 0000 10)

A survival curve graph showing survival probability (%) on the vertical axis and survival time in months on the horizontal axis. The graph compares survival probabilities over time between two groups labeled TPF and PF.*

FDA Label Image

Figure 10 (Doc0b 0000 11)

A Kaplan-Meier survival curve comparing survival probability (%) over time in months for two treatment groups labeled TPF (n=255) and PF (n=246). The graph shows decreasing survival probabilities over a 72-month period with a table below listing the number of patients at risk for each group at multiple time points.*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Doc0b 0000 12)

Label for Docetaxel Injection, USP 80 mg per 8 mL (10 mg per mL) from Sagent Pharmaceuticals. This is an 8 mL multi-dose vial for intravenous use, containing docetaxel anhydrous. The label includes a caution for cytotoxic agent, storage instructions, manufacturing information, and a lot/expiration date area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.